Ansbert Gadicke Sells 57,225 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

by · The Markets Daily

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ansbert Gadicke sold 57,225 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $0.87, for a total value of $49,785.75. Following the sale, the insider owned 4,867,341 shares of the company’s stock, valued at approximately $4,234,586.67. The trade was a 1.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

  • On Thursday, December 4th, Ansbert Gadicke sold 83,230 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $80,733.10.
  • On Tuesday, December 2nd, Ansbert Gadicke sold 59,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $52,756.53.
  • On Monday, December 1st, Ansbert Gadicke sold 60,917 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $57,261.98.
  • On Friday, November 28th, Ansbert Gadicke sold 20,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $20,074.23.
  • On Wednesday, November 26th, Ansbert Gadicke sold 60,733 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $59,518.34.
  • On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $39,130.36.
  • On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $87,025.96.
  • On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73.
  • On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $36,625.28.
  • On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $62,344.56.

Werewolf Therapeutics Trading Down 4.5%

NASDAQ:HOWL opened at $0.95 on Friday. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $2.38. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $46.20 million, a price-to-earnings ratio of -0.59 and a beta of 0.74. The firm has a fifty day simple moving average of $1.37 and a two-hundred day simple moving average of $1.33.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on HOWL shares. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. JMP Securities lowered their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Finally, Bank of America cut their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.75.

View Our Latest Report on Werewolf Therapeutics

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Quadrature Capital Ltd bought a new position in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $28,000. Qube Research & Technologies Ltd purchased a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $48,000. Nuveen LLC bought a new stake in Werewolf Therapeutics during the first quarter worth $71,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the first quarter worth $79,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Werewolf Therapeutics in the second quarter worth $92,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Read More